Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 269

Targeted and Tuned: GPNMB/B7H3 Dual-Targeting CAR T Cells ...

Children diagnosed with diffuse midline glioma (DMG), a devastating brain cancer, face heartbreaking odds. Radiation, the only current treatment, provides limited benefit and causes serious, lifelong side effects. Our mission is to create safer, more effective therapies that give children a real chance to survive and thrive. This project develops ...

A Diffuse Midline Glioma Combination/Multimodality Clinical Trial and Investigation

In this project, we will bring a paradigm-shifting treatment approach, which has led to cures of other previously incurable childhood cancers, to diffuse midline glioma (DMG) for the first time: combination, multimodality therapy. Our clinical trial will incorporate radiation, locally delivered chemotherapy directly to the tumor, systemic chemotherapy to the ...

TARGET-FIRST: Development and optimization of targeted radiopharmaceutical therapies for pediatric ...

Targeted radiopharmaceutical therapy (TRT) is an innovative form of radiation treatment. Unlike conventional external beam radiation therapy (EBRT), which irradiates both tumor and surrounding healthy tissue, TRT uses a radioactive drug that selectively binds tumor cells and delivers radiation directly at the site of disease. This principle has already shown ...

Targeting the tumor microenvironment of DMG with LSD1 inhibition

Diffuse Midline Gliomas or DMGs are a type of brain cancer that primarily arise in children and are incurable.  This proposal will evaluate a novel therapy for DMG that targets an enzyme called LSD1.  We chose to focus on LSD1 as we have preliminary data that LSD1 turns ...

SUMOylation as a novel therapeutic target in DIPG

SUMOylation is a post-translational protein modification (PTM) involved in the control of gene regulation, DNA damage repair, immune responses, and tumor growth.  During the process, SUMO proteins are attached to target proteins by SUMOylation enzymes. Because of its importance in cancer, SUMOylation inhibitors are being developed as therapeutic ...